Клиническая эффективность и безопасность курсовой литолитической терапии больных с хроническим холециститом и билиарным сладжем препаратом Ливодекса

The authors present their own experience litholytic therapy of 68 patients with chronic cholecystitis and biliary sludge using the Livodexa® (Sun Pharmaceutical Industries Ltd, India) at 12 and 24-week course of treatment. In a prospective 24-week investigation was estimated decrease in biliary sludge in the gallbladder as an integral indicator of the effectiveness of litholytic therapy and decline of adverse event during treatment, as an indicator of the safety of treatment.